Protara Therapeutics Inc (NASDAQ:TARA) remains on track to report preliminary results from the ADVANCED-1 trial of TARA-002 in the first half of 2024. The company's cash and cash equivalents stood at $33.77 million as of September 30, 2023.
2023-05-06
negative
Protara Therapeutics: Q1 Earnings Snapshot
Protara Therapeutics, Inc. (TARA) on Thursday reported a loss of $9 million in its first quarter. The New York-based company said it had a Loss of 80 cents per share.
2023-05-04
negative
Protara Therapeutics: Q1 Earnings Snapshot
Protara Therapeutics, Inc. (TARA) reported a loss of $9 million in its first quarter. The New York-based company said it had a Loss of 80 cents per share.
2023-05-04
negative
Protara Therapeutics: Q1 Earnings Snapshot
Protara Therapeutics, Inc. (TARA) on Thursday reported a loss of $9 million in its first quarter. The New York-based company said it had a Loss of 80 cents per share.
2023-03-08
negative
Protara Therapeutics: Q4 Earnings Snapshot
Protara Therapeutics, Inc. (TARA) on Wednesday reported a loss of $39 million in its fourth quarter. For the year, the company reported a Loss of $66 million, or $5.86 per share. Losses, adjusted for asset impairment costs, came to 84 cents pershare.
Sign Up
